Clinical phenotypes in autopsy-confirmed Pick disease

Size: px
Start display at page:

Download "Clinical phenotypes in autopsy-confirmed Pick disease"

Transcription

1 Clinical phenotypes in autopsy-confirmed Pick disease O. Piguet, PhD G.M. Halliday, PhD W.G.J. Reid, PhD B. Casey, PhD R. Carman, MPhil Y. Huang, PhD J.H. Xuereb, MD J.R. Hodges, FRCP J.J. Kril, PhD Address correspondence and reprint requests to Dr. Olivier Piguet, Neuroscience Research Australia, Barker St., Randwick, NSW 2031, Australia ABSTRACT Background: Neuropathology of frontotemporal lobar degeneration is variable and relationship between the pathology and the clinical presentation remains uncertain. Abnormal deposits of hyperphosphorylated and ubiquitinated tau protein are present in 30% of cases, which include the classic presentation of Pick disease with argyrophilic, intraneuronal inclusions known as Pick bodies. This study aimed to improve sensitivity of clinicopathologic relations in cases with neuropathologically confirmed Pick disease and to identify clinical symptoms and signs predictive of disease progression. Methods: This was a retrospective analysis of 21 cases with a pathologic diagnosis of Pick disease and sufficient clinical information to establish early presenting clinical features from 2 specialist centers, representing 70% of all cases of Pick disease identified between 1998 and 2007 in these centers. Results: At presentation, 13/21 cases (62%) were clinically diagnosed with behavioral variant frontotemporal dementia (bvftd) and 8/21 (38%) with language variant frontotemporal dementia (lvftd) including 2 with mixed syndromes. Patients with bvftd died on average 5 years earlier than those with lvftd (7 years vs 12 years after disease onset). Pathologically, fewer Pick bodies were present in the frontal and inferior temporal cortices of bvftd than lvftd cases. In contrast, both groups showed decreased neuronal density in the dentate gyrus with increasing disease duration. Conclusions: The pathologic course of the disease in FTLD cases with Pick bodies is not uniform and disease duration can be estimated based on early clinical features. These findings have relevance as treatment options, which are likely to be pathology specific, are developed. Neurology 2011;76: GLOSSARY bvftd behavioral variant frontotemporal dementia; FTLD frontotemporal lobar degeneration; FUS fused in sarcoma; lvftd language variant frontotemporal dementia; PNFA progressive nonfluent aphasia; SemD semantic dementia; TDP TAR DNA binding protein 43. Frontotemporal lobar degeneration (FTLD) is a progressive neurodegenerative brain disease that encompasses 3 clinical subtypes: behavioral variant frontotemporal dementia (bvftd), semantic dementia (SemD), and progressive nonfluent aphasia (PNFA). 1 All FTLD cases exhibit neuronal loss and gliosis in the frontal or temporal cortices; however, the neuropathology is variable. About 30% of cases exhibit abnormal deposits of hyperphosphorylated and ubiquitinated tau. 2,3 These abnormalities include the classic Pick disease characterized by argyrophilic, intraneuronal Pick bodies and enlarged neurons (Pick cells). About 50% of cases show abnormal deposits of hyperphosphorylated and ubiquitinated TAR DNA binding protein 43 (TDP). Most remaining cases contain abnormal deposits of ubiquitinated fused in sarcoma (FUS) protein, a nuclear ribonucleoprotein. 4 From Neuroscience Research Australia (O.P., G.M.H., W.G.J.R., Y.H., J.R.H.), Sydney; The University of New South Wales (O.P., G.M.H., Y.H., J.R.H.), Sydney; Department of Psychology (B.C.), Concord Repatriation and General Hospital, Sydney; Disciplines of Pathology (R.C., J.J.K.) and Medicine (J.J.K.), Sydney Medical School, The University of Sydney, Sydney, Australia; and Department of Pathology (J.H.X.), University of Cambridge, Cambridge, UK. Study funding: Supported by the National Health and Medical Research Council of Australia (570850). Disclosure: Author disclosures are provided at the end of the article. Copyright 2011 by AAN Enterprises, Inc. 253

2 The relationship between the clinical presentations of FTD and the pathology remains uncertain, particularly for patients with bvftd, who may have tau, TDP, or FUS pathology. 5 The clinical presentation associated with any single pathologic entity of the FTLD spectrum is also not uniform. Tau pathology cases tend to be most commonly associated with bvftd, although some show language FTD or present with motor symptoms. 5,6 The lack of concordance between clinical presentation and neuropathologic substrate is important in the context of the future development of therapeutic disease-modifying agents which will be pathology specific. The aim of this study was to examine cases of FTLD with neuropathologically confirmed Pick disease to ascertain their presenting clinical features. The purpose was twofold: first, to improve sensitivity of clinicopathologic relations; second, to identify clinical symptoms and signs predictive of disease progression. METHODS Review of the Sydney and Cambridge Brain Banks identified 30 cases with a pathologic diagnosis of Pick disease among the nearly 250 FTLD cases collected by these programs between 1992 and Sufficient clinical information to establish a clinical profile was available for 21 of the 30 cases identified (70%). Ten cases (5 men) were from a prospective Brain Donor Program in Sydney, Australia, and 11 cases (6 men) were from the Cambridge Memory and Early Onset Dementia Clinic, Cambridge, UK. We conducted a retrospective analysis of the clinical files and examined all existing medical notes, cognitive test results, as well as patient and informant questionnaires. From this investigation, we obtained the following information for all cases: age at disease onset, disease duration, delay between disease onset and first presentation to the clinic, and age at death. Disease onset was estimated based on carers reports of initial changes. All cases were examined by experienced clinicians. Clinical symptoms and signs and behavioral and cognitive changes at initial presentation were extracted from the files as well as the clinical diagnosis established at the time of presentation. Presence or absence of each core and supporting feature for a clinical diagnosis of FTD (behavioral or language presentation) was established based on existing information. 1 Presence and severity of cognitive deficits at initial presentation were determined from available cognitive test scores and clinical investigations. These were grouped according to the following cognitive domains: attention/concentration, memory, expressive language, receptive language, visuoconstructive abilities, working memory, and executive functions. For the postmortem investigations, the brains were collected, weighed, and immersion fixed in 15% buffered formalin for 2 weeks. Neuropathologic examination was performed to confirm the diagnosis of Pick disease and exclude other diagnoses according to standardized criteria. 7 Briefly, the presence of Pick bodies in the dentate gyrus, hippocampus, and/or cerebral cortex was determined using tau (AT8, Thermo Scientific, Rockford IL; 1:1,000) immunohistochemistry. 8 For this study, fixed tissue blocks were taken from the superior frontal (Brodmann area 8) and inferior temporal (Brodmann area 20) cortices and hippocampus, embedded in paraffin, cut at 10 m, and successive serial sections stained immunohistochemically with ubiquitin (Z0458, DAKO, Denmark; 1:200) and tau (AT8, Thermo Scientific, Rockford IL; 1:1,000) and counterstained with 0.5% cresyl violet, as previously described. 9 The density of Pick bodies and neurons was determined in the dentate gyrus and CA1 region of the hippocampus and in the frontal and temporal cortices using a previously described method. 10 Briefly, a graticule eyepiece measuring 500 m 500 mat200 magnification was used to count the number of neurons containing Pick bodies and the number of nucleolated neurons in 2 strips of cortex perpendicular to the pial surface, and 2 nonoverlapping fields in the dentate gyrus and CA1 region, using standard inclusion and exclusion criteria. The density was calculated by dividing the sum of the counts by the sum of the area. Standard protocol approvals, registrations, and patient consents. This research study was approved by the Universities of Sydney and New South Wales Human Research Ethics Committees and the Addenbrooke s Hospital Local Research Ethics Committee. This study also complies with the statement on human experimentation issued by the National Health and Medical Research Council of Australia. RESULTS Mean disease onset was in the early 60s but was highly variable (table 1). Duration between symptom onset and death was about 9 years on average but was also variable. In 6 individuals, disease duration was 12 years or longer. Disease duration was not significantly related to the age at disease onset. There was no family history of dementia in any of the cases. None of the demographic variables varied significantly between the Sydney and Cambridge samples. At the time of presentation, 13 patients were diagnosed clinically with bvftd and 8 with lvftd. Among these, 4 cases received a clinical diagnosis of PNFA, 3 were diagnosed with SemD (one was also diagnosed with probable AD), and one patient with global aphasic features was diagnosed with FTD, not specified further, or atypical AD. When examining clinical characteristics according to clinical diagnosis, age at onset did not differ between groups. Delay between disease onset and initial presentation to the clinic was shorter in bvftd (2.4 years) compared with lvftd (3.6 years) but did not reach statistical significance (table 1). Disease duration, however, was longer in lvftd than in bvftd cases, confirmed by Kaplan-Meyer survival analysis (p 0.007) (figure). Prevalence of clinical diagnostic criteria. bvftd. At presentation, 11 cases exhibited at least 4 of the 5 core features necessary for a diagnosis of bvftd (i.e., insidious onset, decline in social interpersonal con- 254 Neurology 76 January 18, 2011

3 Table 1 Figure Demographic characteristics in 21 cases with neuropathologically confirmed Pick disease a Total sample (n 21) bvftd (n 13) lvftd (n 8) Mean SD Range Mean SD Range Mean SD Range Sex, F/M 10/11 5/8 5/3 Onset age, y Presentation age, y Time to presentation, y b b Disease duration, y c 6 16 Age at death, y Abbreviations: bvftd behavioral variant frontotemporal dementia; lvftd languagevariant frontotemporal dementia. a No significant differences are present between Sydney and Cambridge cases for any of the variables. b One case with 10 years between onset and presentation. c Difference between lvftd and bvftd ( p 0.015). duct, impaired regulation of personal conduct, emotional blunting, loss of insight). The 2 remaining cases showed preserved emotional response and insight into their condition early in the disease process. Presence of features supportive of the diagnosis of bvftd was variable. The most common features were executive dysfunction (10; 77%), rigidity (8; 61%), distractibility (7; 54%), and mental perseveration (7; 54%). Other supportive features were found in fewer than 5 cases. Importantly, 6 cases (46%) exhibited significant memory deficits as a presenting feature. Survival curve in cases of Pick disease clinically diagnosed as behavioral variant frontotemporal dementia (bvftd) and language variant frontotemporal dementia (lvftd) Disease duration was longer in lvftd cases compared with bvftd cases (p 0.007). lvftd. All 3 SemD cases showed insidious onset and impaired naming and confrontation. Semantic paraphasias and prosopagnosia were reported in 2 cases and empty speech in one. Of the supportive features, change in empathy was most common (all cases). The 4 PNFA cases exhibited nonfluent spontaneous speech. They also showed impaired singleword repetition with phonologic errors and distortions but appeared to have preserved comprehension of simple commands. No disturbance in social skills was reported in this group. One case showed a severe visuoconstructive impairment, being able to copy only simple designs (e.g., cross, square). Cognitive profile. Neuropsychological instruments varied between sites and evolved over the course of data collection. As such, test results were transformed into percentile scores (based on published normative data for age- and education-matched healthy controls), to allow comparison across tests and across participants for each cognitive domain. In some cases, formal neuropsychological examination was not available. In these instances, performance in each cognitive domain was rated as preserved or impaired (mild, moderate, severe) based on information from the clinical file. bvftd. Executive dysfunction was present in all bvftd cases with available data (table 2). The second cognitive domain most commonly affected was memory, with 6 cases exhibiting impaired performance on testing and another case showing a memory deficit specific for visuospatial information. One-third of cases displayed significant deficits on language or visuoconstructive tasks. lvftd. At presentation, one lvftd case (global 1, table 2) had severe expressive and receptive language deficits that prevented formal cognitive assessment. Seen 4 years after disease onset, this person could occasionally follow simple commands but was only capable of unreliable yes/no responses to questions. Among the other cases, naming and comprehension deficits were most common, with relative preservation of the other cognitive domains. One case had impaired episodic memory and 2 cases showed reduced executive function. Working memory and attention/concentration were generally preserved in these patients although these domains were not consistently examined. Neuropathology. Data were missing for the superior frontal cortex for 3 cases and in the inferior temporal cortex for 2 cases (one case with missing data in both regions) due to unavailability of tissue block or insufficient tissue to perform counting. The bvftd group had fewer Pick bodies in the superior frontal (p 0.031) and inferior temporal (p 0.049) cor- Neurology 76 January 18,

4 Table 2 Cognitive profiles in 21 cases with neuropathologically confirmed Pick disease a Case Disease duration, y Delay to presentation, y Memory Language: Expression Language: Comprehension Visuoconstructive Executive WM Attention bvftd Preserved N/A Preserved Preserved N/A bvftd N/A bvftd N/A N/A N/A N/A bvftd N/A N/A N/A N/A bvftd bvftd bvftd N/A 1 N/A N/A N/A bvftd Preserved N/A N/A bvftd N/A bvftd N/A bvftd N/A N/A N/A bvftd bvftd Verbal: 25 50; visuospatial: 1 N/A Preserved SemD Preserved N/A SemD N/A SemD N/A N/A PNFA N/A N/A PNFA Preserved N/A N/A PNFA Preserved N/A N/A N/A PNFA Preserved N/A N/A N/A N/A Global N/A N/A N/A N/A N/A Abbreviations: Mild impairment; moderate impairment; severe impairment; bvftd behavioral variant frontotemporal dementia; lvftd language-variant frontotemporal dementia; N/A information not available in the file; PNFA progressive nonfluent aphasia; SemD semantic dementia; WM working memory. a Scores are percentiles. tices compared to the lvftd group, even after taking into account the longer disease duration of the lvftd group (table 3). None of the other Pick body or neuronal density measures were different between the groups before or after covarying for disease duration, although neuronal density declined in the dentate gyrus with increasing disease duration independent of clinical group (p 0.003). No differences in hippocampal Pick body or neuronal densities were observed between cases with and without memory deficits. To determine the relationship among pathologic variables, including disease duration, principal component analysis was performed for each clinical group. Only factors with eigenvalues 1 which explained 15% of the variance were included. Variables with loadings 0.70 were considered significantly related to each other. In the bvftd group, 2 factors accounted for 66% of the variance (44%, 22%) (table 4). The first factor comprised the 4 Pick body density measures and the second factor disease duration and neuronal loss in the dentate gyrus and CA1 regions. In the lvftd group, 2 factors accounted for 78% of the variance (54%, 24%) (table 4). The first factor included neuronal loss in the dentate gyrus, as expected from above, and decreasing Pick body density in all temporal lobe regions, with disease duration also loading on this factor. The second factor included neuronal loss in other temporal lobe regions. These data show that in bvftd, the severity of Pick bodies in frontal and temporal regions are related, independently of disease duration. In contrast, in lvftd, neuronal loss in the temporal cortex and CA1 region are related, independently of disease duration. DISCUSSION This study details the early clinical presentation of 21 autopsy-confirmed cases of Pick disease. This series, which represents two-thirds of all Pick disease cases collected over 16 years by 2 large brain bank programs, was identified from nearly 250 FTLD cases. It demonstrates that Pick disease is rare, accounting for only 1 in 5 tau-positive cases. This study reveals a number of findings which have clinical implications for the management of 256 Neurology 76 January 18, 2011

5 Table 3 Superior frontal cortex Pick body and neuronal densities in neuropathologically confirmed Pick disease cases according to clinical diagnosis a bvftd (n 13) lvftd (n 8) Mean SD Range Mean SD Range Pick bodies Neurons Inferior temporal cortex Pick bodies Neurons Dentate gyrus Pick bodies , ,560 Neurons 2, ,093 1, ,653 CA1 Pick bodies Neurons Abbreviations: bvftd behavioral variant frontotemporal dementia; lvftd languagevariant frontotemporal dementia. a Density is n/mm 2. FTLD. The clinical features present at initial presentation are associated with clearly different outcomes: patients with bvftd die on average 5 years earlier than those with clinical features consistent with lvftd (7 years vs 12 years after disease onset). In other words, early clinical profiles are indicative of different disease course in cases with the same neuropathology. Various estimates of survival have been reported in lvftd: either being the longest compared with other subtypes of FTD 11 or shorter disease duration in patients with FTD presenting with language disturbance compared to those who do not. 12 This study reports a difference in survival in clinical groups with the same underlying pathology. A previous study, which compared survival in taupositive and tau-negative cases, reported a disease duration in their tau-positive cases that was similar to that of our bvftd cases (7 years). 13 From our findings, we would predict that their FTD group did not contain cases with early language features. In addition, in that study, the sample was not limited to cases with Pick disease but also comprised cases with other tau-positive pathologies, such as corticobasal degeneration, progressive supranuclear palsy, and argyrophilic grain disease. 13 Longer survival has also been reported in Pick disease cases compared with cases with other tau pathology. 5 Interestingly, a recent report on 100 cases of SemD 14 showed a mean disease duration similar to that reported here for the cases with language presentation (13.8 and 12.2 years, respectively). In that study, disease duration in the cases with postmortem confirmation did not differ across pathologic subtypes (tau-positive, TDPpositive, and AD pathologies). In the lvftd group, an unexpected finding was the relatively large number of cases presenting with SemD 3 and one case with global aphasia, compared to those with PNFA. Previous series have reported that presence Table 4 Summary of exploratory factor analyses for the bvftd and lvftd groups Factor loadings bvftd Factor loadings lvftd Pick bodies Disease load Disease load Temporal lobe neuronal loss Dentate G: Pick bodies 0.96 a 0.02 Dentate G: Neuronal loss 0.98 a 0.08 CA1: Pick bodies 0.94 a 0.09 Dentate G: Pick bodies 0.91 a 0.24 Inferior temporal G: Pick bodies Superior frontal G: Pick bodies 0.94 a 0.17 CA1: Pick bodies 0.87 a a 0.12 Inferior temporal G: Pick bodies 0.85 a 0.35 Disease duration a Disease duration 0.77 a 0.11 CA1: Neuronal loss a Inferior temporal G: Neuronal loss a Dentate G: Neuronal loss a CA1: Neuronal loss a Superior frontal G: Neuronal loss Inferior temporal G: Neuronal loss Superior frontal G: Pick bodies Superior frontal G: Neuronal loss Eigenvalues Eigenvalues % of variance % of variance Abbreviations: bvftd behavioral variant frontotemporal dementia; G gyrus; lvftd language-variant frontotemporal dementia. a Factor loadings over Neurology 76 January 18,

6 of SemD tends to predict TDP pathology whereas PNFA tends to predict tau pathology. 5,6,15 Clinicopathologic concordance, however, is not perfect, as shown by the recently published review of a large cohort of SemD cases, 14 and we note that it is possible that the association between PNFA and tau pathology may reflect tau-positive pathology without Pick bodies as described, for instance, as atypical progressive supranuclear palsy. 16 In the present study, neuronal loss in the temporal lobe was characteristic of lvftd cases, consistent with previous studies showing that more severe degeneration in this region occurs in all cases of SemD. 17,18 Results from the factor analysis, however, are exploratory and need to be interpreted cautiously: as many pathologic variables were assessed in only a limited number of cases in our study, this finding will need to be confirmed in a larger cohort of cases. The cognitive profiles in this sample provide further insight into the early clinical presentation in FTLD. Memory complaints and memory deficits documented on formal cognitive testing were common. These deficits were most prominent in the bvftd group, where 7 out of 13 obtained scores well below normal limits. In addition, one case had a severe memory deficit for visuospatial but not verbal material, and another had moderate memory impairment as reported in the clinical notes. Among the lvftd cases, only one experienced significant memory changes. The cause of the episodic memory deficit remains unclear, although hippocampal atrophy has been reported in FTD. 19 In this study, cases with and without memory deficits did not differ with respect to severity of hippocampal pathology in the CA1 region or dentate gyrus. Memory disturbance, however, can also be observed following disturbance in an integrated network that not only comprises the medial temporal lobe region (hippocampus and adjacent cortex) but also includes the mamillary bodies, dorsomedial thalamus, and posterior medial cingulate cortex. 20 Whether the amount of pathology in the extrahippocampal regions of this network differed in the cases with and without memory deficits is not known as these brain regions were not examined in our study. Impaired memory in bvftd has previously been reported. 5,21,22 However, these findings further support the view that a genuine disturbance of episodic memory (i.e., not secondary to faulty retrieval processes) is a possible feature in the initial profile of bvftd and suggest that the presence of memory deficits should not be seen as an exclusion criterion. 23 The prevalence of episodic memory disturbance among Pick disease cases in this study (53%) contrasts with that reported elsewhere recently (7%). 18 In that study, clinical diagnosis was based on the standard criteria, 1 in which memory disturbance represents an exclusion criterion. In addition, it is possible that differences in the types of memory investigations undertaken in the 2 studies may explain the discrepancy in prevalence of memory deficits. The pervasive nature of executive dysfunction in these pathologically confirmed cases provides further evidence that this cognitive deficit is common in bvftd. Although its presence has been thought to be variable, deficits in executive function may have been masked in previous studies by the inclusion of cases presenting with clinical features suggestive of bvftd but who fail to progress to frank dementia over many years (so-called phenocopy or nonprogressive cases). 24 Neuropathologic differences between the clinical subgroups were also present, especially when considering the difference in disease duration, a variable influencing degeneration over time. Our analysis suggests that each clinical group was characterized by a different pathology: neuronal loss in temporal lobe regions occurred in lvftd whereas Pick body deposition characterized bvftd. Importantly, the severity of these pathologies was not related to disease duration. Interestingly, although the density of Pick bodies was lower in bvftd compared with lvftd (table 3), the density of Pick bodies reduced with increased disease duration in the lvftd group. While the contribution of pathologies other than Pick bodies and neuronal loss, or involvement of regions other than those examined, cannot be excluded, these data suggest that neurons that contain Pick bodies are likely targets of neurodegeneration early in bvftd. In lvftd, however, these neurons appear to be affected later in the disease course. Confirmation of these findings in larger cohorts is required. Interestingly, no difference in the severity of pathology was found between cases with and without memory deficit or memory complaint in the 2 regions known to participate in episodic memory function. Because of the retrospective nature of the study, memory integrity was rated only dichotomously and was, arguably, not sensitive enough to detect possible associations between pathology and cognition. The combination of behavioral changes, episodic memory deficits, and executive dysfunction early in the disease process associates with more rapid Pick body related degeneration and a poorer prognosis than language deficits. Importantly, this study confirms that fluent language presentations in FTD are not incompatible with underlying Pick disease, and that temporal lobe neuronal loss underpins these clinical features. In particular, Pick body pathology in lvftd is dependent on disease duration, causing 258 Neurology 76 January 18, 2011

7 neurodegeneration only late in the disease. These findings have relevance as in vivo disease biomarkers (e.g., blood or CSF) are being developed. As such, accurate diagnosis of time-dependent pathologies will ensure optimal pathology-specific therapeutic interventions. AUTHOR CONTRIBUTIONS Statistical analysis was conducted by Dr. O. Piguet and Dr. G.M. Halliday. ACKNOWLEDGMENT Tissues were obtained from the Cambridge Brain Bank, which is supported by the NIHR Cambridge Biomedical Research Centre, and the Sydney Brain Bank, which is supported by the National Health and Medical Research Council of Australia, the University of New South Wales, and Neuroscience Research Australia. DISCLOSURE Dr. Piguet receives research support from the NHMRC and the Australian Research Council. Dr. Halliday has received funding for travel and speaker honoraria from Elan Corporation; serves on the editorial boards of Brain, Acta Neuropathologica, Journal of Neural Transmission, and Movement Disorders; may accrue revenue on a patent(s) re: Genetic test that predicts the progression of Parkinson s disease; receives publishing royalties for Atlas of the Developing Mouse Brain (Elsevier, 2006) and The Human Nervous System, 2nd ed. (Elsevier, 1990); receives research support from NHMRC, the Australian Research Council, Parkinson s NSW; and holds stock/stock options in Cochlear and NIB Holdings. Dr. Reid, Dr. Casey, and Ms. Carman report no disclosures. Dr. Huang may accrue revenue on patent(s) re: Biomarkers for Parkinson s disease; and receives research support from NHMRC. Dr. Xuereb reports no disclosures. Dr. Hodges serves on the Editorial Boards of Aphasiology, Cognitive Neuropsychiatry, and Cognitive Neuropsychology; receives publishing royalties for Cognitive Assessment for Clinicians (Oxford University Press, 2007) and Frontotemporal Dementia Syndromes (Cambridge University Press, 2007); and receives research support from the Australian Research Council. Dr. Kril receives publishing royalties for the recorded lecture series Neuropathology of Dementia (Henry Stewart Publishing, 2007); and receives research support from NHMRC. Received June 14, Accepted in final form September 20, REFERENCES 1. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51: Munoz DG, Dickson DW, Bergeron C, Mackenzie IR, Delacourte A, Zhukareva V. The neuropathology and biochemistry of frontotemporal dementia. Ann Neurol 2003; 54(suppl 5):S24 S Josephs KA, Holton JL, Rossor MN, et al. Frontotemporal lobar degeneration and ubiquitin immunohistochemistry. Neuropathol Appl Neurobiol 2004;30: Neumann M, Rademakers R, Roeber S, Baker M, Kretzschmar HA, Mackenzie IR. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 2009;132: Hodges JR, Davies RR, Xuereb JH, et al. Clinicopathological correlates in frontotemporal dementia. Ann Neurol 2004;56: Kertesz A, McMonagle P, Blair M, Davidson W, Munoz DG. The evolution and pathology of frontotemporal dementia. Brain 2005;128: Halliday G, Ng T, Rodriguez M, et al. Consensus neuropathological diagnosis of common dementia syndromes: testing and standardising Australian practice. Acta Neuropathol 2002;104: Markesbery WR. Pick s disease. In: Markesbery WR, ed. Neuropathology of Dementing Disorders. London: Arnold; 1998: Halliday GM, Song YJ, Lepar G, et al. Pick bodies in a family with presenilin-1 Alzheimer s disease. Ann Neurol 2005;57: Kersaitis C, Halliday GM, Kril JJ. Regional and cellular pathology in frontotemporal dementia: relationship to stage of disease in cases with and without Pick bodies. Acta Neuropathol 2004;108: Hodges JR, Davies R, Xuereb J, Kril J, Halliday G. Survival in frontotemporal dementia. Neurology 2003;61: Roberson ED, Hesse JH, Rose KD, et al. Frontotemporal dementia progresses to death faster than Alzheimer disease. Neurology 2005;65: Xie SX, Forman MS, Farmer J, et al. Factors associated with survival probability in autopsy-proven frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry 2008;79: Hodges JR, Mitchell J, Dawson K, et al. Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. Brain 2010;133: Josephs KA, Petersen RC, Knopman DS, et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 2006;66: Josephs KA, Boeve BF, Duffy JR, et al. Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia. Neurocase 2005;11: Davies RR, Hodges JR, Kril JJ, Patterson K, Halliday GM, Xuereb JH. The pathological basis of semantic dementia. Brain 2005;128: Yokota O, Tsuchiya K, Arai T, et al. Clinicopathological characterization of Pick s disease versus frontotemporal lobar degeneration with ubiquitin/tdp-43-positive inclusions. Acta Neuropathol 2009;117: van de Pol LA, Hensel A, van der Flier WM, et al. Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer s disease. J Neurol Neurosurg Psychiatry 2006;77: Nestor PJ, Fryer TD, Hodges JR. Declarative memory impairments in Alzheimer s disease and semantic dementia. Neuroimage 2006;30: Hornberger M, Shelley BP, Kipps CM, Piguet O, Hodges JR. Can progressive and non-progressive behavioural variant frontotemporal dementia be distinguished at presentation? J Neurol Neurosurg Psychiatry 2009;80: Graham A, Davies R, Xuereb J, et al. Pathologically proven frontotemporal dementia presenting with severe amnesia. Brain 2005;128: Piguet O, Hornberger M, Shelley BP, Kipps CM, Hodges JR. Sensitivity of current criteria for the diagnosis of behavioral variant frontotemporal dementia. Neurology 2009;72: Hornberger M, Piguet O, Kipps C, Hodges JR. Executive function in progressive and nonprogressive behavioral variant frontotemporal dementia. Neurology 2008;71: Neurology 76 January 18,

I do not have any disclosures

I do not have any disclosures Alzheimer s Disease: Update on Research, Treatment & Care Clinicopathological Classifications of FTD and Related Disorders Keith A. Josephs, MST, MD, MS Associate Professor & Consultant of Neurology Mayo

More information

Screening for Cognitive Dysfunction in Corticobasal Syndrome: Utility of Addenbrooke s Cognitive Examination

Screening for Cognitive Dysfunction in Corticobasal Syndrome: Utility of Addenbrooke s Cognitive Examination Original Research Article DOI: 10.1159/000327169 Accepted: March 8, 2011 Published online: April 8, 2011 Screening for Cognitive Dysfunction in Corticobasal Syndrome: Utility of Addenbrooke s Cognitive

More information

The frontotemporal dementia spectrum what the general physician needs to know Dr Jonathan Rohrer

The frontotemporal dementia spectrum what the general physician needs to know Dr Jonathan Rohrer The frontotemporal dementia spectrum what the general physician needs to know Dr Jonathan Rohrer MRC Clinician Scientist Honorary Consultant Neurologist Dementia Research Centre, UCL Institute of Neurology

More information

FRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS

FRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS FRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS Norman L. Foster, M.D. Director, Center for Alzheimer s Care, Imaging and Research Chief, Division of Cognitive Neurology, Department of Neurology

More information

Perspectives on Frontotemporal Dementia and Primary Progressive Aphasia

Perspectives on Frontotemporal Dementia and Primary Progressive Aphasia Perspectives on Frontotemporal Dementia and Primary Progressive Aphasia Bradley F. Boeve, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Alzheimer s Disease

More information

! slow, progressive, permanent loss of neurologic function.

! slow, progressive, permanent loss of neurologic function. UBC ! slow, progressive, permanent loss of neurologic function.! cause unknown.! sporadic, familial or inherited.! degeneration of specific brain region! clinical syndrome.! pathology: abnormal accumulation

More information

How preserved is episodic memory in behavioral variant frontotemporal dementia?

How preserved is episodic memory in behavioral variant frontotemporal dementia? How preserved is episodic memory in behavioral variant frontotemporal dementia? M. Hornberger, PhD O. Piguet, PhD A.J. Graham, PhD, MRCP P.J. Nestor, MD, FRACP J.R. Hodges, MD, FRCP Address correspondence

More information

Form D1: Clinician Diagnosis

Form D1: Clinician Diagnosis Initial Visit Packet Form D: Clinician Diagnosis NACC Uniform Data Set (UDS) ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by the clinician.

More information

Piano playing skills in a patient with frontotemporal dementia: A longitudinal case study

Piano playing skills in a patient with frontotemporal dementia: A longitudinal case study International Symposium on Performance Science ISBN 978-94-90306-01-4 The Author 2009, Published by the AEC All rights reserved Piano playing skills in a patient with frontotemporal dementia: A longitudinal

More information

FTD basics! Etienne de Villers-Sidani, MD!

FTD basics! Etienne de Villers-Sidani, MD! FTD basics! Etienne de Villers-Sidani, MD! Frontotemporal lobar degeneration (FTLD) comprises 3 clinical syndromes! Frontotemporal dementia (behavioral variant FTD)! Semantic dementia (temporal variant

More information

Role of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases

Role of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases Role of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases Keith A. Josephs, MD, MST, MSc Professor of Neurology 13th Annual Mild Cognitive Impairment (MCI) Symposium: Alzheimer and Non-Alzheimer

More information

Sensitivity of current criteria for the diagnosis of behavioral variant frontotemporal dementia

Sensitivity of current criteria for the diagnosis of behavioral variant frontotemporal dementia Sensitivity of current criteria for the diagnosis of behavioral variant frontotemporal dementia O. Piguet, PhD M. Hornberger, PhD B.P. Shelley, MBBS, MD, DM C.M. Kipps, MD, PhD J.R. Hodges, MD, FRCP Address

More information

Frontotemporal dementia and dementia with Lewy bodies in a case-control study of Alzheimer s disease

Frontotemporal dementia and dementia with Lewy bodies in a case-control study of Alzheimer s disease International Psychogeriatrics: page 1 of 8 C 2009 International Psychogeriatric Association doi:10.1017/s1041610209009454 Frontotemporal dementia and dementia with Lewy bodies in a case-control study

More information

Dr Fiona Kumfor University of Sydney

Dr Fiona Kumfor University of Sydney Social Cognition in Dementia: Informing Diagnosis, Prognosis and Management Dr Fiona Kumfor University of Sydney CHANGES IN DEMENTIA Memory Social cognition Language ELEMENTS OF SOCIAL COGNITION Face processing

More information

Dementia Update. Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota

Dementia Update. Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Dementia Update Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Nothing to disclose Dementia Progressive deterioration in mental function

More information

Frontotemporal Dementia: Towards better diagnosis. Frontotemporal Dementia. John Hodges, NeuRA & University of New South Wales, Sydney.

Frontotemporal Dementia: Towards better diagnosis. Frontotemporal Dementia. John Hodges, NeuRA & University of New South Wales, Sydney. I.1 I.2 II.1 II.2 II.3 II.4 II.5 II.6 III.1 III.2 III.3 III.4 III.5 III.6 III.7 III.8 III.9 III.10 III.11 III.12 IV.1 IV.2 IV.3 IV.4 IV.5 Frontotemporal Dementia: Towards better diagnosis Frontotemporal

More information

NIH Public Access Author Manuscript Neurology. Author manuscript; available in PMC 2009 September 2.

NIH Public Access Author Manuscript Neurology. Author manuscript; available in PMC 2009 September 2. NIH Public Access Author Manuscript Published in final edited form as: Neurology. 2008 May 27; 70(22): 2036 2045. doi:10.1212/01.wnl.0000303816.25065.bc. Longitudinal decline in autopsy-defined frontotemporal

More information

LANGUAGE AND PATHOLOGY IN FRONTOTEMPORAL DEGENERATION

LANGUAGE AND PATHOLOGY IN FRONTOTEMPORAL DEGENERATION LANGUAGE AND PATHOLOGY IN FRONTOTEMPORAL DEGENERATION Murray Grossman University of Pennsylvania Support from NIH (AG17586, AG15116, NS44266, NS35867, AG32953, AG38490), IARPA, ALS Association, and the

More information

DEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD

DEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD DEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD OBJECTIVES Terminology/Dementia Basics Most Common Types Defining features Neuro-anatomical/pathological underpinnings Neuro-cognitive

More information

Objectives. Objectives continued: 3/24/2012. Copyright Do not distribute or replicate without permission 1

Objectives. Objectives continued: 3/24/2012. Copyright Do not distribute or replicate without permission 1 Frontotemporal Degeneration and Primary Progressive Aphasia Caregiver and Professional Education Conference Diana R. Kerwin, MD Assistant Professor of Medicine-Geriatrics Cognitive Neurology and Alzheimer

More information

Non Alzheimer Dementias

Non Alzheimer Dementias Non Alzheimer Dementias Randolph B Schiffer Department of Neuropsychiatry and Behavioral Science Texas Tech University Health Sciences Center 9/11/2007 Statement of Financial Disclosure Randolph B Schiffer,,

More information

Clinicopathologic and genetic aspects of hippocampal sclerosis. Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA

Clinicopathologic and genetic aspects of hippocampal sclerosis. Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA Clinicopathologic and genetic aspects of hippocampal sclerosis Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA The hippocampus in health & disease A major structure of the medial temporal

More information

Dementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada

Dementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends

More information

Dementia Past, Present and Future

Dementia Past, Present and Future Dementia Past, Present and Future Morris Freedman MD, FRCPC Division of Neurology Baycrest and University of Toronto Rotman Research Institute, Baycrest CNSF 2015 Objectives By the end of this presentation,

More information

Neuropathology of Neurodegenerative Disorders Prof. Jillian Kril

Neuropathology of Neurodegenerative Disorders Prof. Jillian Kril Neurodegenerative disorders to be discussed Alzheimer s disease Lewy body diseases Frontotemporal dementia and other tauopathies Huntington s disease Motor Neuron Disease 2 Neuropathology of neurodegeneration

More information

Differentiation of semantic dementia and Alzheimer s disease using the Addenbrooke s Cognitive Examination (ACE)

Differentiation of semantic dementia and Alzheimer s disease using the Addenbrooke s Cognitive Examination (ACE) INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY Int J Geriatr Psychiatry 2008; 23: 370 375. Published online 4 September 2007 in Wiley InterScience (www.interscience.wiley.com).1887 Differentiation of semantic

More information

MOTOR FUNCTION AND BEHAVIOUR ACROSS THE ALS-FTD SPECTRUM

MOTOR FUNCTION AND BEHAVIOUR ACROSS THE ALS-FTD SPECTRUM MOTOR FUNCTION AND BEHAVIOUR ACROSS THE ALS-FTD SPECTRUM Dinuksha De Silva, 1, 2 Sharpley Hsieh 4, Jashelle Caga, 4 Felicity V.C. Leslie, 1,2,3 Matthew C. Kiernan, 1, 4 John R. Hodges, 1, 2, 3 Eneida Mioshi,

More information

Do not copy or distribute without permission. S. Weintraub, CNADC, NUFSM, 2009

Do not copy or distribute without permission. S. Weintraub, CNADC, NUFSM, 2009 Sandra Weintraub, Ph.D. Clinical Core Director, Cognitive Neurology and Alzheimer s Disease Center Northwestern University Feinberg School of Medicine Chicago, Illinois Dementia: a condition caused by

More information

DISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT

DISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia DISCLOSURES NONE TO REPORT Freddi Segal Gidan, PA, PhD USC Keck School of Medicine Rancho/USC California Alzheimers Disease

More information

ORIGINAL CONTRIBUTION. Survival Profiles of Patients With Frontotemporal Dementia and Motor Neuron Disease

ORIGINAL CONTRIBUTION. Survival Profiles of Patients With Frontotemporal Dementia and Motor Neuron Disease ORIGINAL CONTRIBUTION Survival Profiles of Patients With Frontotemporal Dementia and Motor Neuron Disease William T. Hu, MD, PhD; Harro Seelaar; Keith A. Josephs, MST, MD; David S. Knopman, MD; Bradley

More information

TDP-43 in the hypoglossal nucleus identifies amyotrophic lateral sclerosis in

TDP-43 in the hypoglossal nucleus identifies amyotrophic lateral sclerosis in TDP-43 in the hypoglossal nucleus identifies amyotrophic lateral sclerosis in behavioral variant frontotemporal dementia Glenda M Halliday a,b, Matthew C Kiernan c, Jillian J Kril d, Remika Mito d, Masami

More information

Neurodegenerative diseases that degrade regions of the brain will eventually become

Neurodegenerative diseases that degrade regions of the brain will eventually become Maren Johnson CD 730 Research Paper What is the underlying neurological explanation for overeating in Frontotemporal Dementia? Does the change in overeating affect swallowing? Neurodegenerative diseases

More information

White matter hyperintensities correlate with neuropsychiatric manifestations of Alzheimer s disease and frontotemporal lobar degeneration

White matter hyperintensities correlate with neuropsychiatric manifestations of Alzheimer s disease and frontotemporal lobar degeneration White matter hyperintensities correlate with neuropsychiatric manifestations of Alzheimer s disease and frontotemporal lobar degeneration Annual Scientific Meeting Canadian Geriatric Society Philippe Desmarais,

More information

Confronting the Clinical Challenges of Frontotemporal Dementia

Confronting the Clinical Challenges of Frontotemporal Dementia Confronting the Clinical Challenges of Frontotemporal Dementia A look at FTD s symptoms, pathophysiology, subtypes, as well as the latest from imaging studies. By Zac Haughn, Senior Associate Editor Ask

More information

Form A3: Subject Family History

Form A3: Subject Family History Initial Visit Packet NACC Uniform Data Set (UDS) Form A: Subject Family History ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by a clinician

More information

review of existing studies on ASL in dementia Marion Smits, MD PhD

review of existing studies on ASL in dementia Marion Smits, MD PhD review of existing studies on ASL in dementia Marion Smits, MD PhD Associate Professor of Neuroradiology Department of Radiology, Erasmus MC, Rotterdam (NL) Alzheimer Centre South-West Netherlands, Rotterdam

More information

Biomarkers: Translating Research into Clinical Practice

Biomarkers: Translating Research into Clinical Practice Biomarkers: Translating Research into Clinical Practice AFTD Education Conference San Diego, April 2015 Nadine Tatton, PhD Scientific Director, AFTD HelpLine 866-5507-7222 u info@theaftd.org u www.theaftd.org

More information

Recent publications using the NACC Database. Lilah Besser

Recent publications using the NACC Database. Lilah Besser Recent publications using the NACC Database Lilah Besser Data requests and publications Using NACC data Number of requests by year Type 2009 2010 2011 2012 2013 2014 2015 Data files* 55 85 217 174 204

More information

Differential Longitudinal Decline on the Mini-Mental State Examination in Frontotemporal Lobar Degeneration and Alzheimer Disease

Differential Longitudinal Decline on the Mini-Mental State Examination in Frontotemporal Lobar Degeneration and Alzheimer Disease ORIGINAL ARTICLE Differential Longitudinal Decline on the Mini-Mental State Examination in Frontotemporal Lobar Degeneration and Alzheimer Disease Kay See Tan, MS,* David J. Libon, PhD,w Katya Rascovsky,

More information

Ruolo dei biomarcatori come criterio di supporto nella diagnostica delle demenze ad esordio precoce

Ruolo dei biomarcatori come criterio di supporto nella diagnostica delle demenze ad esordio precoce Ruolo dei biomarcatori come criterio di supporto nella diagnostica delle demenze ad esordio precoce ALESSANDRO MARTORANA UOC NEUROLOGIA-CENTRO ALZHEIMER POLICLINICO TOR VERGATA-UNIVERSITÀ DI ROMA TOR VERGATA

More information

ORIGINAL CONTRIBUTION

ORIGINAL CONTRIBUTION ORIGINAL CONTRIBUTION Frontotemporal Lobar Degeneration Without Lobar Atrophy Keith A. Josephs, MST, MD; Jennifer L. Whitwell, PhD; Clifford R. Jack, MD; Joseph E. Parisi, MD; Dennis W. Dickson, MD Background:

More information

Executive function in progressive and nonprogressive behavioral variant frontotemporal dementia

Executive function in progressive and nonprogressive behavioral variant frontotemporal dementia Executive function in progressive and nonprogressive behavioral variant frontotemporal dementia Michael Hornberger, PhD Olivier Piguet, PhD Christopher Kipps, MD, FRACP John R. Hodges, MD, FRCP Address

More information

ORIGINAL CONTRIBUTION. Distinct Antemortem Profiles in Patients With Pathologically Defined Frontotemporal Dementia

ORIGINAL CONTRIBUTION. Distinct Antemortem Profiles in Patients With Pathologically Defined Frontotemporal Dementia ORIGINAL CONTRIBUTION Distinct Antemortem Profiles in Patients With Pathologically Defined Frontotemporal Dementia Murray Grossman, MD; David J. Libon, PhD; Mark S. Forman, MD, PhD; Lauren Massimo, LPN;

More information

The Impact of Dementia Severity on Caregiver Burden in Frontotemporal Dementia and Alzheimer Disease

The Impact of Dementia Severity on Caregiver Burden in Frontotemporal Dementia and Alzheimer Disease ORIGINAL ARTICLE The Impact of Dementia Severity on Caregiver Burden in Frontotemporal Dementia and Alzheimer Disease Eneida Mioshi, PhD,*w David Foxe, BPsych,* Felicity Leslie, BPsych,* Sharon Savage,

More information

Neural Correlates of Episodic Memory in Behavioral Variant Frontotemporal Dementia

Neural Correlates of Episodic Memory in Behavioral Variant Frontotemporal Dementia Journal of Alzheimer s Disease 24 (2011) 261 268 DOI 10.3233/JAD-2010-101668 IOS Press 261 Neural Correlates of Episodic Memory in Behavioral Variant Frontotemporal Dementia Catherine Pennington a, John

More information

Activities of Daily Living in Behavioral Variant Frontotemporal Dementia. Differences in Caregiver and Performance-based Assessments

Activities of Daily Living in Behavioral Variant Frontotemporal Dementia. Differences in Caregiver and Performance-based Assessments ORIGINAL ARTICLE Activities of Daily Living in Behavioral Variant Frontotemporal Dementia Differences in Caregiver and Performance-based Assessments Eneida Mioshi, MSc, OTR,*w Christopher M. Kipps, FRACP,zy

More information

Frontal Behavioural Inventory (FBI)

Frontal Behavioural Inventory (FBI) This is a Sample version of the Frontal Behavioural Inventory (FBI) The full version of the Frontal Behavioural Inventory (FBI) comes without sample watermark. The full complete version includes Complete

More information

The behavioural variant frontotemporal dementia phenocopy syndrome is a distinct entity - evidence from a longitudinal study

The behavioural variant frontotemporal dementia phenocopy syndrome is a distinct entity - evidence from a longitudinal study Devenney et al. BMC Neurology (2018) 18:56 https://doi.org/10.1186/s12883-018-1060-1 RESEARCH ARTICLE Open Access The behavioural variant frontotemporal dementia phenocopy syndrome is a distinct entity

More information

Longitudinal patterns of semantic and episodic memory in frontotemporal lobar degeneration and Alzheimer s disease

Longitudinal patterns of semantic and episodic memory in frontotemporal lobar degeneration and Alzheimer s disease Journal of the International Neuropsychological Society (2010), 16, 278 286. Copyright INS. Published by Cambridge University Press, 2009. doi:10.1017/s1355617709991317 Longitudinal patterns of semantic

More information

Mild Cognitive Impairment (MCI)

Mild Cognitive Impairment (MCI) October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine

More information

Differential diagnosis of Frontotemporal Dementia FTLD using visual rating scales

Differential diagnosis of Frontotemporal Dementia FTLD using visual rating scales Differential diagnosis of Frontotemporal Dementia FTLD using visual rating scales Poster No.: C-0491 Congress: ECR 2016 Type: Scientific Exhibit Authors: S. Manouvelou 1, G. ANYFANTAKIS 2, V. Koutoulidis

More information

Frontotemporal dementia:

Frontotemporal dementia: Frontotemporal dementia: Where we ve been What s on the horizon Howard Rosen, M.D. UCSF Department of Neurology Memory and Aging Center www.memory.ucsf.edu None Disclosures Overview FTD, What is it? Origins

More information

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative ORIGINAL RESEARCH E. Matsusue S. Sugihara S. Fujii T. Kinoshita T. Nakano E. Ohama T. Ogawa Cerebral Cortical and White Matter Lesions in Amyotrophic Lateral Sclerosis with Dementia: Correlation with MR

More information

Memory impairment at initial clinical presentation in posterior cortical atrophy

Memory impairment at initial clinical presentation in posterior cortical atrophy Memory impairment at initial clinical presentation in posterior cortical atrophy Samrah Ahmed a, Ian Baker b, Masud Husain a,d, Sian Thompson c, Christopher Kipps e, Michael Hornberger f, John R. Hodges

More information

Prof Tim Anderson. Neurologist University of Otago Christchurch

Prof Tim Anderson. Neurologist University of Otago Christchurch Prof Tim Anderson Neurologist University of Otago Christchurch Tim Anderson Christchurch Insidious cognitive loss From subjective memory complaints (SMC) to dementia Case 1. AR. 64 yrs Male GP referral

More information

Neuro degenerative PET image from FDG, amyloid to Tau

Neuro degenerative PET image from FDG, amyloid to Tau Neuro degenerative PET image from FDG, amyloid to Tau Kun Ju Lin ( ) MD, Ph.D Department of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital ( ) Department of Medical Imaging

More information

Alzheimer s Disease. Clinical characteristics of late-onset Alzheimer s disease (LOAD) A/Prof David Darby

Alzheimer s Disease. Clinical characteristics of late-onset Alzheimer s disease (LOAD) A/Prof David Darby Alzheimer s Disease Clinical characteristics of late-onset Alzheimer s disease (LOAD) A/Prof David Darby Florey Institute of Neuroscience and Mental Health 28-6-2013 The burden of late-onset Alzheimer

More information

Presenter Disclosure Information. I have no financial relationships to disclose:

Presenter Disclosure Information. I have no financial relationships to disclose: Sandra Weintraub, Ph.D. Cognitive Neurology and Alzheimer s Disease Center Northwestern University, Feinberg School of Medicine Chicago, Illinois http://www.brain.northwestern.edu/dementia/ppa/index.html

More information

doi: /brain/awr198 Brain 2011: 134;

doi: /brain/awr198 Brain 2011: 134; doi:10.1093/brain/awr198 Brain 2011: 134; 2565 2581 2565 BRAIN A JOURNAL OF NEUROLOGY Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration Jonathan D. Rohrer,

More information

Development of methodology for conducting clinical trials in frontotemporal lobar degeneration

Development of methodology for conducting clinical trials in frontotemporal lobar degeneration doi:10.1093/brain/awn234 Brain (2008), 131,2957^2968 Development of methodology for conducting clinical trials in frontotemporal lobar degeneration David S. Knopman, 1 Joel H. Kramer, 2 Bradley F. Boeve,

More information

2016 Programs & Information

2016 Programs & Information Mayo Alzheimer s Disease Research Clinic Education Center 2016 Programs & Information BROCHURE TITLE FLUSH RIGHT for Persons & Families impacted by Mild Cognitive Impairment Alzheimer s Disease Dementia

More information

Clinical Genetics & Dementia

Clinical Genetics & Dementia Clinical Genetics & Dementia Dr Nayana Lahiri Consultant in Clinical Genetics & Honorary Senior Lecturer Nayana.lahiri@nhs.net Aims of the Session To appreciate the potential utility of family history

More information

What is. frontotemporal. address? dementia?

What is. frontotemporal. address? dementia? What is frontotemporal address? dementia? Contents 03 What is frontotemporal dementia? 04 Symptoms 05 Diagnosis 06 Treatments Information in this booklet is for anyone who wants to know more about frontotemporal

More information

Objectives. RAIN Difficult Diagnosis 2014: A 75 year old woman with falls. Case History: First visit. Case History: First Visit

Objectives. RAIN Difficult Diagnosis 2014: A 75 year old woman with falls. Case History: First visit. Case History: First Visit Objectives RAIN Difficult Diagnosis 2014: A 75 year old woman with falls Alexandra Nelson MD, PhD UCSF Memory and Aging Center/Gladstone Institute of Neurological Disease Recognize important clinical features

More information

Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review

Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review 1 Department of Neurology, Erasmus MCdUniversity Medical Centre Rotterdam, Rotterdam, The Netherlands 2 Dementia Research Centre, UCL Institute of Neurology, London, UK 3 Department of Neurology, VU University

More information

ALS, Cognitive Impairment (CI) and Frontotemporal Lobar Dementia (FTLD): A Professional s Guide

ALS, Cognitive Impairment (CI) and Frontotemporal Lobar Dementia (FTLD): A Professional s Guide ALS, Cognitive Impairment (CI) and Frontotemporal Lobar Dementia (FTLD): A Professional s Guide Overview A link between ALS and cognitive dysfunction was first noted in the late 1800 s, but only in the

More information

The ABCs of Dementia Diagnosis

The ABCs of Dementia Diagnosis The ABCs of Dementia Diagnosis Dr. Robin Heinrichs, Ph.D., ABPP Board Certified Clinical Neuropsychologist Associate Professor, Psychiatry & Behavioral Sciences Director of Neuropsychology Training What

More information

Brain Advance Access published February 25, doi: /brain/awu024 Brain 2014: Page 1 of 17 1

Brain Advance Access published February 25, doi: /brain/awu024 Brain 2014: Page 1 of 17 1 Brain Advance Access published February 25, 2014 doi:10.1093/brain/awu024 Brain 2014: Page 1 of 17 1 BRAIN A JOURNAL OF NEUROLOGY Asymmetry and heterogeneity of Alzheimer s and frontotemporal pathology

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Devenney E, Bartley L, Hoon C, et al. Progression in behavioral variant frontotemporal dementia: a longitudinal study. JAMA Neurol. Published online October 26, 2015. doi:10.1001/jamaneurol.2015.2061.

More information

Frontotemporal dementia : a clinical-pathological study

Frontotemporal dementia : a clinical-pathological study Acta neurol. belg., 2001, 101, 224-229 Clinical Pathological Conference Frontotemporal dementia : a clinical-pathological study A. MICHOTTE 1,2, S. GOLDMAN 3, P. TUGENDHAFT 4 and D. ZEGERS DE BEYL 4 1

More information

Dementia and Aphasia-AD, FTD & aphasia

Dementia and Aphasia-AD, FTD & aphasia 特別講演 Dementia and Aphasia-AD, FTD & aphasia Shunichiro Shinagawa, Bruce L. Miller Key words : Alzheimer s disease, frontotemporal dementia, primary progressive aphasia Alzheimer s disease(ad)and frontotemporal

More information

Frontotemporal Dementia and Related Disorders: Deciphering the Enigma

Frontotemporal Dementia and Related Disorders: Deciphering the Enigma NEUROLOGICAL PROGRESS Frontotemporal Dementia and Related Disorders: Deciphering the Enigma Keith A. Josephs, MST, MD In the past century, particularly the last decade, there has been enormous progress

More information

O Connor 1. Appendix e-1

O Connor 1. Appendix e-1 O Connor 1 Appendix e-1 Neuropsychiatric assessment The Cambridge Behavioural Inventory Revised (CBI-R) 1, 2 is a proxy behavioural questionnaire that has been extensively used in studies involving FTD

More information

Significant cognitive improvement with cholinesterase inhibition in AD with cerebral amyloid angiopathy

Significant cognitive improvement with cholinesterase inhibition in AD with cerebral amyloid angiopathy Paterson, Abdi 1 Significant cognitive improvement with cholinesterase inhibition in AD with cerebral amyloid angiopathy Ross W Paterson MRCP 1 *, Zeinab Abdi MRCP 1 *, Amanda Haines RMN 1, Jonathan M

More information

Frontotemporal. dementia. Features, diagnosis and management. Neurology. Frontal lobe function. Background. Objective. Discussion

Frontotemporal. dementia. Features, diagnosis and management. Neurology. Frontal lobe function. Background. Objective. Discussion Neurology Frontotemporal Daniel KY Chan Sharon Reutens Dennis KW Liu Richard O Chan Features, diagnosis and management Background Frontotemporal is the third or fourth most common form of in the 45 65

More information

FRONTO TEMPORAL DEMENTIA

FRONTO TEMPORAL DEMENTIA FRONTO TEMPORAL DEMENTIA Dr. Diana Paleacu Kertesz Neurology Service and Memory Clinic Abarbanel Mental Health Center Department of Neurology, Tel Aviv University DAT: 55-60% VD: 15-20% DLBD: 15-20% FTD:

More information

FRONTO TEMPORAL DEMENTIA

FRONTO TEMPORAL DEMENTIA FRONTO TEMPORAL DEMENTIA Dr. Diana Paleacu Kertesz Neurology Service and Memory Clinic Abarbanel Mental Health Center Department of Neurology, Tel Aviv University Fronto-Temporal Lobe Dementia (FTLD) DAT:

More information

Differential Diagnosis

Differential Diagnosis Differential Diagnosis 2 2.1 Introduction AD accounts for up to 75 % of all dementia cases. The differential diagnosis with other conditions is sometimes challenging since several disorders may produce

More information

What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia

What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia Dementia: broad term for any acquired brain condition impairing mental function such that ADLs are impaired. Includes:

More information

Early Onset Dementia From the background to the foreground

Early Onset Dementia From the background to the foreground Early Onset Dementia From the background to the foreground Dr Jeremy Isaacs Consultant Neurologist St George s Hospital Excellence in specialist and community healthcare Themes of my talk The early onset

More information

Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech

Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech doi:10.1093/brain/awl078 Brain (2006), 129, 1385 1398 Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech Keith A. Josephs, 1,2 Joseph R. Duffy, 3 Edyth A. Strand, 3

More information

8/24/18. Dementia. Risk of Dementia Following Traumatic Brain Injury: A Review of the Literature. Media Presence. Media Presence

8/24/18. Dementia. Risk of Dementia Following Traumatic Brain Injury: A Review of the Literature. Media Presence. Media Presence Risk of Dementia Following Traumatic Brain Injury: A Review of the Literature Media Presence Carlos Marquez de la Plata, Ph.D. & Jeff Schaffert, M.S. Media Presence Dementia What is dementia? Dementia

More information

ORIGINAL CONTRIBUTION. Clinical and Psychometric Distinction of Frontotemporal and Alzheimer Dementias

ORIGINAL CONTRIBUTION. Clinical and Psychometric Distinction of Frontotemporal and Alzheimer Dementias ORIGINAL CONTRIBUTION Clinical and Psychometric Distinction of Frontotemporal and Alzheimer Dementias Rajka M. Liscic, MD, PhD; Martha Storandt, PhD; Nigel J. Cairns, PhD; John C. Morris, MD Background:

More information

What is frontotemporal dementia?

What is frontotemporal dementia? What is frontotemporal dementia? Introduction Information in this introductory booklet is for anyone who wants to know more about frontotemporal dementia (FTD). This includes people living with FTD, their

More information

Behavioural variant frontotemporal dementia with dominant gait disturbances case report

Behavioural variant frontotemporal dementia with dominant gait disturbances case report Psychiatr. Pol. 2016; 50(2): 329 336 PL ISSN 0033-2674 (PRINT), ISSN 2391-5854 (ONLINE) www.psychiatriapolska.pl DOI: http://dx.doi.org/10.12740/pp/58937 Behavioural variant frontotemporal dementia with

More information

FTD/PPA Caregiver Education Conference March 11, 2011

FTD/PPA Caregiver Education Conference March 11, 2011 FTD/PPA Caregiver Education Conference March 11, 2011 Question and Answer Session Answered by Joseph Cooper, MD, Darby Morhardt, MSW, LCSW, Mary O Hara, AM, LCSW, Jaimie Robinson, MSW, LCSW, Emily Rogalski,

More information

ORIGINAL CONTRIBUTION. Clinically Undetected Motor Neuron Disease in Pathologically Proven Frontotemporal Lobar Degeneration With Motor Neuron Disease

ORIGINAL CONTRIBUTION. Clinically Undetected Motor Neuron Disease in Pathologically Proven Frontotemporal Lobar Degeneration With Motor Neuron Disease ORIGINAL CONTRIBUTION Clinically Undetected Motor Neuron Disease in Pathologically Proven Frontotemporal Lobar Degeneration With Motor Neuron Disease Keith A. Josephs, MST, MD; Joseph E. Parisi, MD; David

More information

Diagnosis before NIA AA The impact of FDG PET in. Diagnosis after NIA AA Neuropathology and PET image 2015/10/16

Diagnosis before NIA AA The impact of FDG PET in. Diagnosis after NIA AA Neuropathology and PET image 2015/10/16 The impact of FDG PET in degenerative dementia diagnosis Jung Lung, Hsu MD, Ph.D (Utrecht) Section of dementia and cognitive impairment Department of Neurology Chang Gung Memorial Hospital, Linkou, Taipei

More information

Lecture 42: Final Review. Martin Wessendorf, Ph.D.

Lecture 42: Final Review. Martin Wessendorf, Ph.D. Lecture 42: Final Review Martin Wessendorf, Ph.D. Lecture 33 cortex Heilbronner 5 lobes of the cortex Lateral view (left side) Mid-saggital view (right side) Cellular organization of cortex White matter

More information

Brain imaging for the diagnosis of people with suspected dementia

Brain imaging for the diagnosis of people with suspected dementia Why do we undertake brain imaging in dementia? Brain imaging for the diagnosis of people with suspected dementia Not just because guidelines tell us to! Exclude other causes for dementia Help confirm diagnosis

More information

Neuropsychological, Behavioral, and Anatomical Evolution in Right Temporal Variant Frontotemporal Dementia: A Longitudinal Single Case Analysis

Neuropsychological, Behavioral, and Anatomical Evolution in Right Temporal Variant Frontotemporal Dementia: A Longitudinal Single Case Analysis Neuropsychological, Behavioral, and Anatomical Evolution in ight Temporal Variant Frontotemporal Dementia: A Longitudinal Single Case Analysis Introduction Frontotemporal dementia (FTD) comprises a group

More information

Visual Rating Scale Reference Material. Lorna Harper Dementia Research Centre University College London

Visual Rating Scale Reference Material. Lorna Harper Dementia Research Centre University College London Visual Rating Scale Reference Material Lorna Harper Dementia Research Centre University College London Background The reference materials included in this document were compiled and used in relation to

More information

doi: /brain/awp232 Brain 2009: 132;

doi: /brain/awp232 Brain 2009: 132; doi:10.1093/brain/awp232 Brain 2009: 132; 2932 2946 2932 BRAIN A JOURNAL OF NEUROLOG Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study Jennifer

More information

September 3-5, 2008 Rotterdam, The Netherlands

September 3-5, 2008 Rotterdam, The Netherlands Sixth International Conference on Frontotemporal Dementia September 3-5, 2008 Rotterdam, The Netherlands June 12, 2007 For all enquiries please contact: Status Plus Conferences P.O. Box 97 3950 AB Maarn,

More information

NIH Public Access Author Manuscript Neuropsychology. Author manuscript; available in PMC 2010 May 1.

NIH Public Access Author Manuscript Neuropsychology. Author manuscript; available in PMC 2010 May 1. NIH Public Access Author Manuscript Published in final edited form as: Neuropsychology. 2009 May ; 23(3): 337 346. doi:10.1037/a0014995. Neuropsychological Decline in Frontotemporal Lobar Degeneration:

More information

Define functional MRI. Briefly describe fmri image acquisition. Discuss relative functional neuroanatomy. Review clinical applications.

Define functional MRI. Briefly describe fmri image acquisition. Discuss relative functional neuroanatomy. Review clinical applications. Dr. Peter J. Fiester November 14, 2012 Define functional MRI. Briefly describe fmri image acquisition. Discuss relative functional neuroanatomy. Review clinical applications. Briefly discuss a few examples

More information

ORIGINAL CONTRIBUTION. Deformation-Based Morphometry Reveals Brain Atrophy in Frontotemporal Dementia

ORIGINAL CONTRIBUTION. Deformation-Based Morphometry Reveals Brain Atrophy in Frontotemporal Dementia ORIGINAL CONTRIBUTION Deformation-Based Morphometry Reveals Brain Atrophy in Frontotemporal Dementia Valerie A. Cardenas, PhD; Adam L. Boxer, MD, PhD; Linda L. Chao, PhD; Maria L. Gorno-Tempini, MD, PhD;

More information

Biochimica et Biophysica Acta

Biochimica et Biophysica Acta Biochimica et Biophysica Acta 1822 (2012) 325 332 Contents lists available at ScienceDirect Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbadis Review Structural brain imaging

More information

Does corticobasal degeneration exist? A clinicopathological re-evaluation

Does corticobasal degeneration exist? A clinicopathological re-evaluation doi:10.1093/brain/awq123 Brain 2010: 133; 2045 2057 2045 BRAIN A JOURNAL OF NEUROLOGY Does corticobasal degeneration exist? A clinicopathological re-evaluation Helen Ling, 1,2 Sean S. O Sullivan, 1,2 Janice

More information

Update on functional brain imaging in Movement Disorders

Update on functional brain imaging in Movement Disorders Update on functional brain imaging in Movement Disorders Mario Masellis, MSc, MD, FRCPC, PhD Assistant Professor & Clinician-Scientist Sunnybrook Health Sciences Centre University of Toronto 53 rd CNSF

More information